Related Experiment Videos
Phase I trial of diaziquone (AZQ) plus GM-CSF
L C Hartmann1, M M Ames, J M Reid
1Mayo Clinic, Rochester, MN 55905, USA.
Investigational New Drugs
|January 1, 1995
Abstract:
Diaziquone (AZQ) is a lipid soluble alkylating agent which was designed for increased CNS penetration. Its principle toxicity is myelosuppression. We conducted a phase I trial using AZQ in combination with GM-CSF to determine if the maximal tolerate dose (MTD) of AZQ could be escalated. Using GM-CSF on a standard schedule, we were unable to escalate the previously determined MTD of diaziquone with the use of this colony stimulating factor.